Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions (NASDAQ:ARQT)

IvelinRadkov/iStock via Getty Images

Mizuho cut its rating of Arcutis Biotherapeutics (NASDAQ:ARQT) to neutral and slashed its price target, citing lower than expected prescriptions for the drug roflumilast.

The investment bank said it had been bullish on the stock because it believed the market

Leave a Comment